Earnings Feed

VXRT

Healthcare

BARDA will continue funding follow-up for approximately 5,000 participants dosed in the COVID-19 trial despite the stop work order.
Cash, cash equivalents, and investments totaled $26.3 million at the end of Q2 2025.
Cash runway is expected to last into Q1 2026 based on current plans.
Q2 2025 revenue was $39.7 million, up significantly from $6.4 million in Q2 2024, primarily driven by the BARDA contract awarded in June 2024.
R&D expenses are expected to be partially reimbursed by BARDA, with over 50% of the original contract anticipated to be collected.
The company implemented workforce reductions totaling approximately 31% over Q1 and Q2 2025 to reduce operating costs.

TBPH

Healthcare

Cash position remained strong at approximately $340 million with near cash-neutral operations and expected $27 million in taxes related to the TRELEGY sale accrued in Q2.
Collaboration revenue grew 31% year-over-year, driven by YUPELRI sales growth and improved profit margins.
Non-GAAP losses improved to $4.2 million compared to $6.3 million in the prior year, excluding onetime items.
The company recognized a $7.5 million milestone payment following YUPELRI's regulatory approval in China.
Theravance Biopharma reported strong Q2 2025 financial results with YUPELRI net sales reaching approximately $66 million, a 22% year-over-year increase, marking the highest Q2 sales since launch.
Theravance completed the $225 million sale of its remaining TRELEGY royalty interest to GSK, recognizing $75 million of other income and strengthening the balance sheet.

MRVI

Healthcare

1mo

Adjusted EBITDA was negative $10.4 million in Q2 2025 versus positive $13 million in Q2 2024.
Basic and diluted EPS loss was $0.27 per share compared to $0.07 loss in Q2 2024; adjusted EPS loss was $0.08 versus $0.01 loss in prior year.
BST segment revenue grew 10% year-over-year to $16.3 million with an adjusted EBITDA margin of 67%.
Cash balance ended at $270 million with $297 million in long-term debt; cash used in operations was $10.3 million.
GAAP net loss was $69.8 million in Q2 2025 compared to $18.4 million loss in Q2 2024.
NAP segment revenue was $31.1 million with a 3% year-over-year increase in base business, showing sequential growth from Q1 2025.
Q2 2025 revenue was $47.4 million, down from $69.4 million in Q2 2024, but base revenue excluding high-volume CleanCap increased by 5%.

Healthcare

Capital expenditures totaled $103 million; 85 million shares repurchased and $71 million paid in dividends.
Earnings per share (EPS) for Q3 were $1.37, growing 4% year-over-year and at the high end of expectations.
Gross margin declined to 53.1% due to currency, tariffs, and BioVectra capacity expansion downtime.
Net leverage ratio remained strong at 0.9x at quarter-end.
Operating cash flow was $362 million, down year-over-year due to working capital increases and severance costs.
Operating margin was 25.1%, consistent but below expectations due to tariffs, variable pay, and commercial investments.
Q3 revenue was $1.74 billion, exceeding guidance with 6.1% core growth and 10.1% reported growth.